Order Article Reprints

Cabibbo G, Celsa C, Enea M, Battaglia S, Rizzo GEM, Busacca A, Matranga D, Attanasio M, Reig M, Craxì A, et al. Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. Cancers. 2021; 13(1):90. https://doi.org/10.3390/cancers13010090

Cabibbo, Giuseppe, Ciro Celsa, Marco Enea, Salvatore Battaglia, Giacomo Emanuele Maria Rizzo, Anita Busacca, Domenica Matranga, Massimo Attanasio, Maria Reig, Antonio Craxì, and et al. 2021. "Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma" Cancers 13, no. 1: 90. https://doi.org/10.3390/cancers13010090

Cabibbo, G., Celsa, C., Enea, M., Battaglia, S., Rizzo, G. E. M., Busacca, A., Matranga, D., Attanasio, M., Reig, M., Craxì, A., & Cammà, C. (2021). Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. Cancers, 13(1), 90. https://doi.org/10.3390/cancers13010090